Scarica l'app Stockscreener
681.58
1.68%
-11.65
Pre-mercato:
685.00
3.42
+0.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Clear Harbor Asset Management LLC Buys 3,006 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Lmcg Investments LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
404 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Mechanics Bank Trust Department - MarketBeat
MassMutual Private Wealth & Trust FSB Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Regeneron Pharmaceuticals (REGN) Faces Securities Class - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman - GlobeNewswire Inc.
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Cove Private Wealth LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
2025-01-20 | REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm - GuruFocus.com
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to - The Bakersfield Californian
ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron - GlobeNewswire
Moss Adams Wealth Advisors LLC Buys 923 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Monarch Capital Management Inc. Acquires 549 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’ - Insider Monkey
AdvisorNet Financial Inc Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
B & T Capital Management DBA Alpha Capital Management Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Boston Common Asset Management LLC - MarketBeat
Avanza Fonder AB Makes New $7.41 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - StreetInsider.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Procyon Advisors LLC - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron - GlobeNewswire
Robbins LLP Urges REGN Stockholders with Large Losses to - GlobeNewswire
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Woodstock Corp Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Kilgore News Herald
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact L - GuruFocus.com
2025-01-17 | REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REGN | Press Release - Stockhouse Publishing
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN - Morningstar
Outlook Wealth Advisors LLC Invests $305,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report - Nasdaq
Fifth Third Wealth Advisors LLC Has $783,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance
UBS Downgrades Regeneron Pharmaceuticals (REGN) - MSN
What to Expect From Regeneron Pharmaceuticals's Q4 2024 Earnings Report - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - Stockhouse Publishing
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron Executives Sued for Medicare Overbilling, Stock Drop - Bloomberg Law
Regeneron Pharmaceuticals, Inc. Securities Fraud Class - GlobeNewswire
UBS cuts rating on Regeneron stock amid Eylea uncertainty - Investing.com
What To Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report - Barchart
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers - AOL
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by UBS Group - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Connective Portfolio Management LLC - MarketBeat
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Inves - GuruFocus.com
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Regeneron Pharmaceuticals, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the REGN Class Action - AccessWire
Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
1.21%
2.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):